<![CDATA[ABSTRACT Prognosis in individuals undergoing in-vitro fertilization (IVF) is often assessed using anti-other commonly employed laboratory methods. Blood samples from 120 low-prognosis females undergoing IVF treatment at the ASHA Infertility Clinic, Primasatya Husada Citra Hospital, Surabaya, Indonesia, were analyzed using both Cobas e411 (Roche) and Maglumi X3 (SNIBE) platforms. The Cobas employs electrochemiluminescence immunoassays (ECLIA), while Maglumi X3 utilizes CLIA labelled with N-(4-aminobutyl)-N-ethylisoluminol (ABEI). The concordance of the tests was evaluated using Spearman's rank correlation, Passing-Bablok regression, and Bland-Altman statistical analyses. The median AMH value was 2.55 ng/dL for Cobas e411 and 2.54 ng/dL for Maglumi X3. The Passing-Bablok regression analysis yielded an intercept of -0.0064 (95% CI: -0.0400 to 0.0296) and a slope of 0.9869 (95% CI: 0.9689 to 1.0000), indicating no significant bias. The Spearman correlation analysis between the two methods stated a strongly positive correlation (p=0.985, p<0.0001). The Bland-Altman analysis indicated an average bias of -0.05, implying that the Maglumi X3 measures AMH levels lower than the Cobas e411, with the limits of agreement (LoA) spanning from -1.1 to 1.0. The AMH test performed using the Maglumi X3 (SNIBE) demonstrates a strong correlation and consistency with the current laboratory test (Cobas e411), making it a reliable alternative for measuring AMH levels. However, the results should be interpreted alongside other clinical parameters and observations.]]>
Copyrights © 2025
